{"slideshow_credits": null, "snippet": "Critics have raised an outcry over Sovaldi, a hepatitis C drug heralded as a breakthrough but costing $84,000 for a typical person\u2019s total treatment.", "abstract": "The Upshot column; critics have raised an outcry over hepatitis C drug Sovaldi, heralded as a breakthrough but costing $1,000 a pill and about $84,000 for a typical person\u2019s total treatment; drug from maker Gilead Sciences cures about 90 percent of patients who take it; advocates say quick cure for hepatitis C can cost a lot less than a lifetime of treatments for other diseases.", "section_name": "The Upshot", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Margot", "role": "reported", "lastname": "SANGER-KATZ", "rank": 1, "organization": ""}], "original": "By MARGOT SANGER-KATZ", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/08/03/upshot/is-a-1000-pill-really-too-much.html", "lead_paragraph": "Critics have raised an outcry over Sovaldi, a hepatitis C drug heralded as a breakthrough but costing $84,000 for a typical person\u2019s total treatment.", "headline": {"print_headline": "Is a $1,000 Pill Really Too Much?", "seo": "Critics Raise Concerns About Sovaldi", "main": "$1,000 Hepatitis Pill Shows Why Fixing Health Costs Is So Hard", "content_kicker": "Public Health", "kicker": "The Upshot"}, "_id": "53dd121038f0d8266c78fec0", "word_count": "1519", "multimedia": [{"height": 126, "url": "images/2014/08/02/upshot/03UP-Sovaldi/03UP-Sovaldi-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/08/02/upshot/03UP-Sovaldi/03UP-Sovaldi-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2014/08/02/upshot/03UP-Sovaldi/03UP-Sovaldi-articleLarge.jpg", "legacy": {"xlarge": "images/2014/08/02/upshot/03UP-Sovaldi/03UP-Sovaldi-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/08/02/upshot/03UP-Sovaldi/03UP-Sovaldi-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/08/02/upshot/03UP-Sovaldi/03UP-Sovaldi-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-08-03T00:00:00Z", "source": "The New York Times", "news_desk": "SundayBusiness", "keywords": [{"name": "subject", "value": "Hepatitis", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Sovaldi (Drug)", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Gilead Sciences Inc", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Health Insurance and Managed Care", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}